

7. Anhang

7.1 Literaturverzeichnis

1. Meuer SC, Hussey RE, Fabbi M, et al. An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. *Cell* 1984;36:897-906.
2. Somoza C, Driscoll PC, Cyster JG, Williams AF. Mutational analysis of the CD2/CD58 interaction: the binding site for CD58 lies on one face of the first domain of human CD2. *J Exp Med* 1993;178:549-58.
3. Arulanandam AR, Withka JM, Wyss DF, et al. The CD58 (LFA-3) binding site is a localized and highly charged surface area on the AGFCC'C" face of the human CD2 adhesion domain. *Proc Natl Acad Sci U S A* 1993;90:11613-7.
4. Peterson A, Seed B. Monoclonal antibody and ligand binding sites of the T cell erythrocyte receptor (CD2). *Nature* 1987;329:842-6.
5. Briskin MJ, McEvoy LM, Butcher EC. MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1. *Nature* 1993;363:461-4.
6. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. *Cell* 1993;74:185-95.
7. Pirzer UC, Schurmann G, Post S, Meuer SC. Differential responsiveness to CD3-Ti vs CD2 dependent activation of human intestinal T lymphocytes. *Eur J Immunol* 1990;20:2339-42.
8. Zeitz M, Quinn TC, Graeff AS, James SP. Mucosal T cells provide helper function but do not proliferate when stimulated by specific antigen in lymphogranuloma venereum proctitis in nonhuman primates. *Gastroenterology* 1988;94:353-366.
9. Zeitz M, Schieferdecker HL, Ullrich R, et al. Phenotype and function of lamina propria T lymphocytes. *Immunol Res* 1991;10:199-206.
10. Boirivant M, Fuss I, Fiocchi C, et al. Hypoproliferative human lamina propria T cells retain the capacity to secrete lymphokines when stimulated via CD2/CD28 pathways. *Proc Assoc Am Physicians* 1996;108:55-67.
11. Qiao L, Schurmann G, Betzler M, Meuer SC. Down-regulation of protein kinase C activation in human lamina propria T lymphocytes: influence of intestinal mucosa on T cell reactivity. *Eur J Immunol* 1991;21:2385-9.
12. Qiao L, Schurmann G, Betzler M, Meuer SC. Activation and signaling status of human lamina propria T lymphocytes. *Gastroenterology* 1991;101:1529-36.
13. Gonsky R, Deem RL, Young HA, Targan SR. CD2 mediates activation of the IFN-gamma intronic STAT binding region in mucosal T cells. *Eur J Immunol* 2003;33:1152-62.
14. Braunstein J, Qiao L, Autschbach F, Schurmann G, Meuer S. T cells of the human intestinal lamina propria are high producers of interleukin-10. *Gut* 1997;41:215-20.
15. Sido B, Giese T, Autschbach F, et al. Potential role of thioredoxin in immune responses in intestinal lamina propria T lymphocytes. *Eur J Immunol* 2005;35:408-17.
16. Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. *J Immunol* 1993;150:4338-45.
17. Boirivant M, Pica R, DeMaria R, et al. Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. *J Clin Invest* 1996;98:2616-22.
18. Duchmann R, Lochs H, Kruis W. [Crohn disease, ulcerative colitis. When bacteria attack the intestinal wall...]. *MMW Fortschr Med* 1999;141:48-51.
19. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. *J Immunol* 1996;157:1261-70.
20. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. *Immunity* 2002;17:629-38.

21. Fiocchi C, Hilfiker ML, Youngman KR, Doerder NC, Finke JH. Interleukin 2 activity of human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel disease. *Gastroenterology* 1984;86:734-42.
22. Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. *Gastroenterology* 1992;102:1620-7.
23. Fais S, Capobianchi MR, Pallone F, et al. Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. *Gut* 1991;32:403-7.
24. Monteleone G, Trapasso F, Parrello T, et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. *J Immunol* 1999;163:143-7.
25. Pizarro TT, Michie MH, Bentz M, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. *J Immunol* 1999;162:6829-35.
26. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. *Am J Pathol* 1997;150:823-32.
27. Monteleone G, MacDonald TT, Wathen NC, Pallone F, Pender SL. Enhancing Lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. *Gastroenterology* 1999;117:1069-77.
28. Matsuura T, West GA, Levine AD, Fiocchi C. Selective resistance of mucosal T-cell activation to immunosuppression in Crohn's disease. *Dig Liver Dis* 2000;32:484-94.
29. Ueyama H, Kiyohara T, Sawada N, et al. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. *Gut* 1998;43:48-55.
30. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. *J Immunol* 1999;163:1081-90.
31. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. *Gastroenterology* 1999;116:557-65.
32. Itoh J, de La Motte C, Strong SA, Levine AD, Fiocchi C. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. *Gut* 2001;49:35-41.
33. Hoffmann JC, Pawlowski NN, Kuhl AA, Hohne W, Zeitz M. Animal models of inflammatory bowel disease: an overview. *Pathobiology* 2002;70:121-30.
34. Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. *Immunity* 1994;1:553-62.
35. Autenrieth IB, Bucheler N, Bohn E, Heinze G, Horak I. Cytokine mRNA expression in intestinal tissue of IL-2 deficient mice with bowel inflammation. *Gut* 1997;41:793-800.
36. Davidson NJ, Leach MW, Fort MM, et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. *J Exp Med* 1996;184:241-51.
37. Mizoguchi A, Mizoguchi E, Chiba C, et al. Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. *J Exp Med* 1996;183:847-56.
38. Mombaerts P, Mizoguchi E, Grusby MJ, et al. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. *Cell* 1993;75:274-82.
39. Madara JL, Podolsky DK, King NW, et al. Characterization of spontaneous colitis in cotton-top tamarins (*Saguinus oedipus*) and its response to sulfasalazine. *Gastroenterology* 1985;88:13-9.
40. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. *J Exp Med* 1998;188:1929-39.
41. Rudolph A, Bonhagen K, Reimann J. Polyclonal expansion of adoptively transferred CD4+ alpha beta T cells in the colonic lamina propria of scid mice with colitis. *Eur J Immunol* 1996;26:1156-63.

42. Aranda R, Sydora BC, McAllister PL, et al. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. *J Immunol* 1997;158:3464-73.
43. Claesson MH, Bregenholt S, Bonhagen K, et al. Colitis-inducing potency of CD4+ T cells in immunodeficient, adoptive hosts depends on their state of activation, IL-12 responsiveness, and CD45RB surface phenotype. *J Immunol* 1999;162:3702-10.
44. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. *J Exp Med* 1994;179:589-600.
45. Trobonjaca Z, Leithauser F, Moller P, et al. MHC-II-independent CD4+ T cells induce colitis in immunodeficient RAG-/- hosts. *J Immunol* 2001;166:3804-12.
46. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. *Int Immunol* 1993;5:1461-71.
47. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. *Immunity* 1995;3:171-4.
48. Liesenfeld O, Kosek J, Remington JS, Suzuki Y. Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with *Toxoplasma gondii*. *J Exp Med* 1996;184:597-607.
49. Liesenfeld O. Oral infection of C57BL/6 mice with *Toxoplasma gondii*: a new model of inflammatory bowel disease? *J Infect Dis* 2002;185 Suppl 1:S96-101.
50. Davis SJ, van der Merwe PA. The structure and ligand interactions of CD2: implications for T-cell functions. *Immunol.Today* 1996;17:177-187.
51. Yagita H, Nakamura T, Asakawa J, et al. CD2 expression in murine B cell lineage. *Int Immunol* 1989;1:94-8.
52. Keogh MC, Elliot J, Norton T, Lake RA. A function for CD2 on murine B cells? *Immunol Cell Biol* 1997;75:333-9.
53. Yagita H, Okumura K, Nakauchi H. Molecular cloning of the murine homologue of CD2. Homology of the molecule to its human counterpart T11. *J Immunol*. 1988;140:1321-1326.
54. Steinman RM. The dendritic cell system and its role in immunogenicity. *Annu Rev Immunol* 1991;9:271-96.
55. Crawford K, Stark A, Kitchens B, et al. CD2 engagement induces dendritic cell activation: implications for immune surveillance and T-cell activation. *Blood* 2003;102:1745-52.
56. Alberola-Illa J, Places L, de la Calle O, et al. Stimulation through the TCR/CD3 complex up-regulates the CD2 surface expression on human T lymphocytes. *J Immunol* 1991;146:1085-92.
57. Bierer BE, Burakoff SJ. T-lymphocyte activation: the biology and function of CD2 and CD4. *Immunol Rev* 1989;111:267-94.
58. van der Merwe PA. Formation and function of the immunological synapse. *Curr Opin Immunol* 2002;14:293-8.
59. Yang H, Reinherz EL. Dynamic recruitment of human CD2 into lipid rafts. Linkage to T cell signal transduction. *J Biol Chem* 2001;276:18775-85.
60. Bromley SK, Burack WR, Johnson KG, et al. The immunological synapse. *Annu Rev Immunol* 2001;19:375-96.
61. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. *Nature* 1998;395:82-6.
62. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. *Science* 1999;285:221-7.
63. van Der Merwe PA, Davis SJ. Immunology. The immunological synapse--a multitasking system. *Science* 2002;295:1479-80.
64. Lee KH, Holdorf AD, Dustin ML, et al. T cell receptor signaling precedes immunological synapse formation. *Science* 2002;295:1539-42.
65. Wakkach A, Cottrez F, Groux H. Differentiation of regulatory T cells 1 is induced by CD2 costimulation. *J Immunol* 2001;167:3107-13.

66. Bullens DM, Rafiq K, Charitidou L, et al. Effects of co-stimulation by CD58 on human T cell cytokine production: a selective cytokine pattern with induction of high IL-10 production. *Int Immunol* 2001;13:181-91.
67. Guckel B, Berek C, Lutz M, et al. Anti-CD2 antibodies induce T cell unresponsiveness in vivo. *J Exp Med* 1991;174:957-67.
68. Bell GM, Imboden JB. CD2 and the regulation of T cell anergy. *J Immunol* 1995;155:2805-7.
69. Boussiotis VA, Freeman GJ, Griffin JD, et al. CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. *J Exp Med* 1994;180:1665-73.
70. Brown MH, Sewell WA, Mason DY, Rothbard JB, Crumpton MJ. Species conservation of the T cell lymphocyte CD2 cell surface antigen. *Eur J Immunol* 1988;18:1223-7.
71. Arulanandam AR, Kister A, McGregor MJ, et al. Interaction between human CD2 and CD58 involves the major beta sheet surface of each of their respective adhesion domains. *J Exp Med* 1994;180:1861-71.
72. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against *Mycobacterium tuberculosis* in mice. *Immunity* 1995;2:561-72.
73. Hahn WC, Bierer BE. Separable portions of the CD2 cytoplasmic domain involved in signaling and ligand avidity regulation. *J Exp Med* 1993;178:1831-6.
74. Bierer BE, Bogart RE, Burakoff SJ. Partial deletions of the cytoplasmic domain of CD2 result in a partial defect in signal transduction. *J Immunol* 1990;144:785-9.
75. Kato K, Koyanagi M, Okada H, et al. CD48 is a counter-receptor for mouse CD2 and is involved in T cell activation. *J Exp. Med* 1992;176:1241-1249.
76. Selvaraj P, Plunkett ML, Dustin M, et al. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. *Nature* 1987;326:400-403.
77. Krensky AM, Sanchez-Madrid F, Robbins E, et al. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. *J Immunol* 1983;131:611-6.
78. Smith ME, Thomas JA. Cellular expression of lymphocyte function associated antigens and the intercellular adhesion molecule-1 in normal tissue. *J Clin Pathol* 1990;43:893-900.
79. Hahn WC, Menu E, Bothwell AL, Sims PJ, Bierer BE. Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. *Science* 1992;256:1805-7.
80. Deckert M, Kubar J, Zoccola D, et al. CD59 molecule: a second ligand for CD2 in T cell adhesion. *Eur J Immunol* 1992;22:2943-7.
81. van der Merwe PA, Barclay AN, Mason DW, et al. Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59. *Biochemistry* 1994;33:10149-60.
82. Menu E, Tsai BC, Bothwell AL, Sims PJ, Bierer BE. CD59 costimulation of T cell activation. CD58 dependence and requirement for glycosylation. *J Immunol* 1994;153:2444-56.
83. Jones EY, Davis SJ, Williams AF, Harlos K, Stuart DI. Crystal structure at 2.8 Å resolution of a soluble form of the cell adhesion molecule CD2. *Nature* 1992;360:232-9.
84. Bodian DL, Jones EY, Harlos K, Stuart DI, Davis SJ. Crystal structure of the extracellular region of the human cell adhesion molecule CD2 at 2.5 Å resolution. *Structure* 1994;2:755-66.
85. Garboczi DN, Ghosh P, Utz U, et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. *Nature* 1996;384:134-41.
86. Teng MK, Smolyar A, Tse AG, et al. Identification of a common docking topology with substantial variation among different TCR-peptide-MHC complexes. *Curr Biol* 1998;8:409-12.
87. Wild MK, Cambiaggi A, Brown MH, et al. Dependence of T cell antigen recognition on the dimensions of an accessory receptor-ligand complex. *J Exp Med* 1999;190:31-41.
88. Kozarsky KF, Tsai C, Bott CM, et al. An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites. *Cell Immunol* 1993;150:235-46.
89. Wesselborg S, Prufer U, Wild M, et al. Triggering via the alternative CD2 pathway induces apoptosis in activated human T lymphocytes. *Eur J Immunol* 1993;23:2707-10.

90. Ayroldi E, Zollo O, Cannarile L, et al. Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death. *Blood* 1998;92:4212-9.
91. Chavin KD, Lau HT, Bromberg JS. Prolongation of allograft and xenograft survival in mice by anti- CD2 monoclonal antibodies. *Transplantation* 1992;54:286-291.
92. Sido B, Otto G, Zimmermann R, et al. Modulation of the CD2 receptor and not disruption of the CD2/CD48 interaction is the principal action of CD2-mediated immunosuppression in the rat. *Cell Immunol* 1997;182:57-67.
93. Sido B, Dengler TJ, Otto G, et al. Differential immunosuppressive activity of monoclonal CD2 antibodies on allograft rejection versus specific antibody production. *Eur J Immunol* 1998;28:1347-57.
94. Hirahara H, Tsuchida M, Watanabe T, et al. Long-term survival of cardiac allografts in rats treated before and after surgery with monoclonal antibody to CD2. *Transplantation* 1995;59:85-90.
95. Haga M, Hirahara H, Tsuchida M, et al. Costimulatory signal blockade by anti-CD2 monoclonal antibody in combination with 15-deoxyspergualin prolongs concordant xenograft survival. *Transplant Proc* 2000;32:1006-8.
96. Barlow AK, Like AA. Anti-CD2 monoclonal antibodies prevent spontaneous and adoptive transfer of diabetes in the BB/Wor rat. *Am J Pathol* 1992;141:1043-51.
97. Hoffmann JC, Herklotz C, Zeidler H, Bayer B, Westermann J. Anti-CD2 (OX34) MoAb treatment of adjuvant arthritic rats: attenuation of established arthritis, selective depletion of CD4+ T cells, and CD2 down-modulation. *Clin Exp Immunol* 1997;110:63-71.
98. Hoffmann JC, Herklotz C, Zeidler H, et al. Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34. *Ann Rheum Dis* 1997;56:716-22.
99. Jung S, Toyka K, Hartung HP. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. *Eur J Immunol*. 1995;25:1391-1398.
100. Inomata T, Watanabe T, Haga M, et al. Anti-CD2 monoclonal antibodies prevent the induction of experimental autoimmune myocarditis. *Jpn Heart J* 2000;41:507-17.
101. Snanoudj R, Rouleau M, Bidere N, et al. A role for CD2 antibodies (BTI-322 and its humanized form) in the in vivo elimination of human T lymphocytes infiltrating an allogeneic human skin graft in SCID mice: an Fcγ receptor-related mechanism involving co-injected human NK cells. *Transplantation* 2004;78:50-8.
102. Przepiorka D, Phillips GL, Ratanatharathorn V, et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. *Blood* 1998;92:4066-71.
103. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. *Arch Dermatol* 2003;139:719-27.
104. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. *N Engl J Med* 2001;345:248-55.
105. Chamian F, Lowes MA, Lin SL, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. *Proc Natl Acad Sci U S A* 2005;102:2075-80.
106. Nizet Y, Chentoufi AA, de la Parra B, et al. The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322. *Transplantation* 2000;69:1420-8.
107. Hodak E, David M. Alefacept: a review of the literature and practical guidelines for management. *Dermatol Ther* 2004;17:383-92.
108. Martin PJ, Longton G, Ledbetter JA, et al. Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50. *J Immunol* 1983;131:180-5.
109. Wild MK, Strittmatter W, Matzku S, Schraven B, Meuer SC. Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy. *J Immunol* 1999;163:2064-72.

110. Henschke S, Pawlowski NN, Wild MK, et al. Lamina propria T cell activation: role of the costimulatory molecule CD2 and its cytoplasmic tail for the regulation of proliferation and apoptosis. *Int J Colorectal Dis* 2005;1-11.
111. Fleischer B. A novel pathway of human T cell activation via a 103 kD T cell activation antigen. *J Immunol* 1987;138:1346-50.
112. Huet S, Wakasugi H, Sterkers G, et al. T cell activation via CD2 [T, gp50]: the role of accessory cells in activating resting T cells via CD2. *J Immunol* 1986;137:1420-8.
113. Verbi W, Greaves MF, Schneider C, et al. Monoclonal antibodies OKT11 and OKT11A have pan-T reactivity and block sheep erythrocyte "receptors". *Eur J Immunol* 1982;12:81-6.
114. Sanchez-Madrid F, Krensky AM, Ware CF, et al. Three distinct antigens associated with human T-lymphocyte-mediated cytotoxicity: LFA-1, LFA-2, and LFA-3. *Proc Natl Acad Sci U S A* 1982;79:7489-93.
115. Holter W, Majdic O, Lyszka K, Stockinger H, Knapp W. Kinetics of activation antigen expression by in vitro-stimulated human T lymphocytes. *Cell Immunol* 1985;90:322-30.
116. Fournel S, Robinet E, Bonnefoy-Berard N, et al. A noncomitogenic CD2R monoclonal antibody induces apoptosis of activated T cells by a CD95/CD95-L-dependent pathway. *J Immunol* 1998;160:4313-21.
117. Lang G, Wotton D, Owen MJ, et al. The structure of the human CD2 gene and its expression in transgenic mice. *Embo J* 1988;7:1675-82.
118. Killeen N, Stuart SG, Littman DR. Development and function of T cells in mice with a disrupted CD2 gene. *Embo J* 1992;11:4329-36.
119. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. *J Immunol Methods* 2000;243:147-54.
120. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. *J.Exp.Med.* 1995;182:1281-1290.
121. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. *Immunity* 2004;21:491-501.
122. Chavin KD, Qin L, Lin J, Kaplan AJ, Bromberg JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. *Transplantation* 1993;55:901-8.
123. Altevogt P, Kohl U, Von Hoegen P, Lang E, Schirmacher V. Antibody 12-15 cross-reacts with mouse Fc gamma receptors and CD2: study of thymus expression, genetic polymorphism and biosynthesis of the CD2 protein. *Eur J Immunol* 1989;19:341-6.
124. Chavin KD, Qin L, Yon R, et al. Anti-CD2 mAbs suppress cytotoxic lymphocyte activity by the generation of Th2 suppressor cells and receptor blockade. *J Immunol* 1994;152:3729-39.
125. Woodward JE, Qin L, Chavin KD, et al. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways. *Transplantation* 1996;62:1011-8.
126. Latchman Y, Reiser H. Enhanced murine CD4+ T cell responses induced by the CD2 ligand CD48. *Eur J Immunol* 1998;28:4325-31.
127. Autschbach F, Schurmann G, Qiao L, et al. Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease. *Virchows Arch* 1995;426:51-60.
128. Binion DG, West GA, Volk EE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. *Lancet* 1998;352:1742-6.
129. Burns RC, Rivera-Nieves J, Moskaluk CA, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. *Gastroenterology* 2001;121:1428-36.
130. Bregenholt S, Reimann J, Claesson MH. Proliferation and apoptosis of lamina propria CD4+ T cells from scid mice with inflammatory bowel disease. *Eur J Immunol* 1998;28:3655-63.

131. Murata Y, Ishiguro Y, Itoh J, Munakata A, Yoshida Y. The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. *J Gastroenterol* 1995;30 Suppl 8:56-60.
132. Wittig B, Schwarzler C, Fohr N, Gunthert U, Zoller M. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. *J Immunol* 1998;161:1069-73.
133. Ludviksson BR, Strober W, Nishikomori R, Hasan SK, Ehrhardt RO. Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-/- mice. *J Immunol* 1999;162:4975-82.
134. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. *Gastroenterology* 1996;111:1373-80.
135. Lin J, Chavin KD, Qin L, Ding Y, Bromberg JS. Anti-CD2 monoclonal antibody-induced receptor changes. II. Interaction of CD2 and CD3. *Cell Immunol* 1996;167:249-58.
136. Bromberg JS, Chavin KD, Altevogt P, et al. Anti-CD2 monoclonal antibodies alter cell-mediated immunity in vivo. *Transplantation* 1991;51:219-25.
137. Lin J, Yon RW, Chavin KD, et al. Anti-CD2 monoclonal antibody-induced receptor changes: down modulation of cell surface CD2. *Transplantation* 1995;59:1162-71.
138. Sasada T, Yang H, Reinherz EL. CD2 facilitates differentiation of CD4 Th cells without affecting Th1/Th2 polarization. *J Immunol* 2002;168:1113-22.
139. van der Merwe PA. A subtle role for CD2 in T cell antigen recognition. *J Exp Med* 1999;190:1371-4.
140. Mourad M, Besse T, Malaise J, et al. BTI-322 for acute rejection after renal transplantation. *Transplant Proc* 1997;29:2353.
141. Palacios R, Martinez-Maza O. Is the E receptor on human T lymphocytes a "negative signal receptor"? *J Immunol* 1982;129:2479-85.
142. Bai Y, Fu S, Honig S, et al. CD2 is a dominant target for allogeneic responses. *Am J Transplant* 2002;2:618-26.
143. Ida H, Anderson P. Activation-induced NK cell death triggered by CD2 stimulation. *Eur J Immunol* 1998;28:1292-300.
144. Hoffmann JC, Peters K, Henschke S, et al. Role of T lymphocytes in rat 2,4,6-trinitrobenzene sulphonic acid (TNBS) induced colitis: increased mortality after gammadelta T cell depletion and no effect of alphabeta T cell depletion. *Gut* 2001;48:489-95.
145. Chavin KD, Qin L, Lin J, et al. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production. *Ann Surg* 1993;218:492-501; discussion 501-3.
146. Musgrave BL, Watson CL, Haeryfar SM, Barnes CA, Hoskin DW. CD2-CD48 interactions promote interleukin-2 and interferon-gamma synthesis by stabilizing cytokine mRNA. *Cell Immunol* 2004;229:1-12.
147. Rosenthal-Allieri MA, Ticchioni M, Deckert M, et al. Monocyte-independent T cell activation by simultaneous binding of three CD2 monoclonal antibodies (D66 + T11.1 + GT2). *Cell Immunol* 1995;163:88-95.
148. Howard FD, Moingeon P, Moebius U, et al. The CD3 zeta cytoplasmic domain mediates CD2-induced T cell activation. *J Exp Med* 1992;176:139-45.
149. Gromo G, Geller RL, Inverardi L, Wee SL, Bach FH. Role of CD2 and IL 1 beta in T cell responsiveness to IL 2. *J Immunol* 1987;138:2155-60.
150. Musgrave BL, Watson CL, Hoskin DW. CD2-CD48 interactions promote cytotoxic T lymphocyte induction and function: anti-CD2 and anti-CD48 antibodies impair cytokine synthesis, proliferation, target recognition/adhesion, and cytotoxicity. *J Interferon Cytokine Res* 2003;23:67-81.
151. Reed JC, Tadmori W, Kamoun M, Koretzky G, Nowell PC. Suppression of interleukin 2 receptor acquisition by monoclonal antibodies recognizing the 50 KD protein associated

- with the sheep erythrocyte receptor on human T lymphocytes. *J Immunol* 1985;134:1631-9.
152. Stohl W, Linker-Israeli M. Inhibitory effects of anti-CD2 monoclonal antibodies on interleukin 2 production and interleukin 2 receptor expression in anti-CD3-induced T cell activation. *Cell Immunol* 1989;120:351-65.
 153. Gonsky R, Deem RL, Hughes CC, Targan SR. Activation of the CD2 pathway in lamina propria T cells up-regulates functionally active AP-1 binding to the IL-2 promoter, resulting in messenger RNA transcription and IL-2 secretion. *J Immunol* 1998;160:4914-22.
 154. Tadmori W, Reed JC, Nowell PC, Kamoun M. Functional properties of the 50 kd protein associated with the E-receptor on human T lymphocytes: suppression of IL 2 production by anti-p50 monoclonal antibodies. *J Immunol* 1985;134:1709-16.
 155. Stohl W, Posnett DN, Chiorazzi N. Differential immunomodulation by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell activation: dependence upon the individual anti-CD3 monoclonal antibody used for activation. *Cell Immunol* 1988;116:73-85.
 156. Butler JJ, Mader JS, Watson CL, et al. Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: role of interleukin-2 and cyclic AMP signaling pathways. *J Cell Biochem* 2003;89:975-91.
 157. Appleman LJ, Boussiotis VA. T cell anergy and costimulation. *Immunol Rev* 2003;192:161-80.
 158. Buer J, Lanoue A, Franzke A, et al. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. *J Exp Med* 1998;187:177-83.
 159. Lin J, Gettys TW, Qin L, et al. Increased cAMP and cAMP-dependent protein kinase activity mediate anti-CD2 induced suppression of anti-CD3-driven interleukin-2 production and CD25 expression. *Pathobiology* 1995;63:175-87.
 160. Chavin KD, Qin L, Lin J, Yagita H, Bromberg JS. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model. *J Immunol* 1993;151:7249-59.
 161. Qin L, Chavin KD, Lin J, Yagita H, Bromberg JS. Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. *J Exp Med* 1994;179:341-6.
 162. Pitzalis C, Pipitone N, Bajocchi G, et al. Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. *J Immunol* 1997;158:5007-16.
 163. Migliorati G, Bartoli A, Nocentini G, et al. Dexamethasone modulates CD2 expression. *Int J Immunopharmacol* 1996;18:677-84.
 164. Thanasak J, Jorritsma R, Hoek A, et al. The effects of a single injection of dexamethasone-21-isonicotinate on the lymphocyte functions of dairy cows at two weeks post partum. *Vet Res* 2004;35:103-12.
 165. Pipitone N, Sinha M, Theodoridis E, et al. The glucocorticoid inhibition of LFA-1 and CD2 expression by human mononuclear cells is reversed by IL-2, IL-7 and IL-15. *Eur J Immunol* 2001;31:2135-42.
 166. Moingeon P, Lucich JL, McConkey DJ, et al. CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells. *Proc Natl Acad Sci U S A* 1992;89:1492-6.
 167. Brown MH, Monostori E, Gullberg M, et al. Structure-function relationships of the human T lymphocyte CD2 antigen. *Cold Spring Harb Symp Quant Biol* 1989;54 Pt 2:627-36.
 168. Verhagen AM, Schraven B, Wild M, Wallich R, Meuer SC. Differential interaction of the CD2 extracellular and intracellular domains with the tyrosine phosphatase CD45 and the zeta chain of the TCR/CD3/zeta complex. *Eur J Immunol* 1996;26:2841-9.
 169. Xu Y, Kolber-Simonds D, Hope JA, et al. The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletion. *Clin Exp Immunol* 2004;138:476-83.
 170. Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. *Blood* 2003;102:284-8.

171. da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. *J Immunol* 2002;168:4462-71.
172. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. *J Immunol* 1994;152:2753-67.
173. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *N Engl J Med* 1997;337:1029-35.
174. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001;345:1098-104.
175. Liesenfeld O, Kang H, Park D, et al. TNF-alpha, nitric oxide and IFN-gamma are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with *Toxoplasma gondii*. *Parasite Immunol* 1999;21:365-76.
176. Bachmann MF, Barner M, Kopf M. CD2 sets quantitative thresholds in T cell activation. *J Exp Med* 1999;190:1383-92.
177. Evans CF, Rall GF, Killeen N, Littman D, Oldstone MB. CD2-deficient mice generate virus-specific cytotoxic T lymphocytes upon infection with lymphocytic choriomeningitis virus. *J Immunol* 1993;151:6259-64.
178. Beck JM, Blackmon MB, Rose CM, et al. T cell costimulatory molecule function determines susceptibility to infection with *Pneumocystis carinii* in mice. *J Immunol* 2003;171:1969-77.
179. Vossenkamper A, Struck D, Alvarado C, et al. Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with *Toxoplasma gondii*, but IL-12 is dominant over IL-18 in parasite control. *Eur J Immunol* 2004;34:3197-207.
180. Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. *Inflamm Bowel Dis* 1998;4:285-90.
181. Scharton-Kersten TM, Wynn TA, Denkers EY, et al. In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to *Toxoplasma gondii* while failing to control acute infection. *J Immunol* 1996;157:4045-54.
182. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: the major mediator of resistance against *Toxoplasma gondii*. *Science* 1988;240:516-8.
183. Mahida YR, Kurlac L, Gallagher A, Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. *Gut* 1991;32:1531-4.
184. Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. *Gastroenterology* 1992;102:514-9.
185. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. *Lancet* 1992;339:89-91.
186. Maeda M, Watanabe N, Neda H, et al. Serum tumor necrosis factor activity in inflammatory bowel disease. *Immunopharmacol Immunotoxicol* 1992;14:451-61.
187. Lee WT, Yin XM, Vitetta ES. Functional and ontogenetic analysis of murine CD45Rhi and CD45Rlo CD4+ T cells. *J Immunol* 1990;144:3288-95.
188. Dustin ML, Golan DE, Zhu DM, et al. Low affinity interaction of human or rat T cell adhesion molecule CD2 with its ligand aligns adhering membranes to achieve high physiological affinity. *J Biol Chem* 1997;272:30889-98.
189. Nakamura T, Takahashi K, Fukazawa T, et al. Relative contribution of CD2 and LFA-1 to murine T and natural killer cell functions. *J Immunol* 1990;145:3628-34.
190. Duplay P, Lancki D, Allison JP. Distribution and ontogeny of CD2 expression by murine T cells. *J Immunol* 1989;142:2998-3005.

7.2 Danksagung

Zwar zuletzt, aber sicherlich nicht an letzter Stelle möchte ich mich bei all denen bedanken, die mir auf unterschiedlichste Weise bei der Anfertigung dieser Arbeit mit Rat und Tat zur Seite standen.

Besonders danken möchte ich

... PD Dr. Jörg Hoffmann für die Überlassung des interessanten Themas, für seine Anleitung zum selbstständigen Arbeiten, sowie für seine Unterstützung und Anregungen bei der Durchführung dieser Arbeit

... meinen Kolleginnen Anja Kühl und Katja Grollich, da wir ein nahezu unschlagbares Team waren und weil ich ohne sie oft verzweifelt wäre

... Prof. Oliver Liesenfeld und Daniela Struck, die mir eine sehr große Hilfe bei der Durchführung und histologischen Auswertung der Toxoplasmen-versuche waren

... Dr. Christoph Loddenkämper für die Beurteilung der histologischen Schnitte

... Arvind Batra und Jana Droese für die kritische Durchsicht des Manuskriptes und für ihre konstruktiven Verbesserungsvorschläge

... Dr. Britta Siegmund, die sich immer Zeit genommen hat, mir mit Ratschlägen und Diskussionen ein wenig auf die Sprünge zu helfen

... den Tierpflegern des FEM, insbesondere Sabine Steinbach und Jeanette Wagner für die bereitwillige freundliche Hilfe während meiner Arbeit mit den Mäusen

... allen Kollegen, die immer wieder Blut für mich lassen mussten

... meinen Freunden, dass sie für mich da waren, wenn mal wieder nichts lief, wie es eigentlich sollte, und auch, wenn ausnahmsweise mal alles klappte.

Außerdem möchte ich meiner Mutter und meinem zu früh verstorbenen Vater danken.

Ohne sie wäre ich weder die, die ich bin, noch da, wo ich bin.

7.3 Tabellarischer Lebenslauf

Persönliche Daten

Name, Vorname	Pawlowski, Nina
Geburtsdatum, -ort	20.02.1976, Krefeld
Familienstand	ledig
Staatsbürgerschaft	deutsch
Eltern	Hans-Ulrich Pawlowski, geb. in Friedeberg Gisela Pawlowski, geb. Küsters, geb. in Moers
Geschwister	Viola Pawlowski, geb. in Krefeld

Schulbildung, Studium und Beruf

1982-1986	Grundschule an der Landwehrstraße in Moers
1986-1995	Gymnasium Adolfinum in Moers, Abschluss Abitur
1995-2000	Studium der Biopharmakologie an der Ernst-Moritz-Arndt-Universität in Greifswald, Abschluss Diplom
2000-2001	Wissenschaftliche Mitarbeiterin im Institut für Immunologie und Transfusionsmedizin an der Ernst-Moritz-Arndt-Universität in Greifswald
2001-2005	Doktorandin im Institut für Gastroenterologie der Medizinischen Klinik I, der Medizinischen Fakultät der Charité, Campus Benjamin Franklin

7.4 Eigene Publikationen

Während dieser Arbeit wurden folgende Publikationen und Kongressbeiträge erstellt:

Publikationen:

Jörg C. Hoffmann, Nina N. Pawlowski, Anja A. Kühl, Wolfgang Höhne, Martin Zeitz. "Animal Models of Inflammatory Bowel Disease: An Overview" in Pathobiology 2002-03, 70:121-130.

J.C. Hoffmann, N.N. Pawlowski, A.A. Kühl. "New Research Aspects of Crohn's Disease: Animal Models" in State of the Art: Current Research Strategies in Crohn's Disease, Digestive Surgery 2003, 20: 339-382.

Nina N. Pawlowski, Hacer Kakirman, Anja A. Kühl, Oliver Liesenfeld, Katja Grollich, Christoph Loddenkemper, Martin Zeitz, Jörg C. Hoffmann: "Anti-CD2 mAb treatment safely attenuates adoptive transfer colitis", Lab. Invest. 2005, 85: 1013-1023

Sven Henschke, Nina N. Pawlowski, Martin Wild, Anton Kroesen, Martin Zeitz, Jörg C. Hoffmann: "Lamina propria T cell activation: Role of the costimulatory molecule CD2 and its cytoplasmic tail for the regulation of proliferation and apoptosis", Int. J. Colorectal Dis. 2005, 23: 1-11.

Anja A. Kühl, Hacer Kakirman, Markus Janotta, Stefan Dreher, Philipp Cremer, Nina N. Pawlowski, Christoph Loddenkemper, Katja Grollich, Martin Zeitz, Stefan Farkas, Jörg C. Hoffmann: "Role of Neutrophil Invasion in Rat Tri-/Dinitrobenzene sulfonic acid induced Colitis", *zur Publikation eingereicht*.

Anja A. Kühl, Nina N. Pawlowski, Katja Grollich, Christoph Loddenkemper, Martin Zeitz, Jörg C. Hoffmann, 2005. Aggravation of intestinal Inflammation by Depletion/Deficiency of $\gamma\delta$ T Cells in different Types of IBD Animal Models; *zur Publikation eingereicht*.

Posterbeiträge:

Nina N. Pawlowski, Anja A. Kühl, Hacer Kakirman, Sven Henschke, Sabine Ring, Martin Zeitz, Jörg C. Hoffmann. "CD2 directed immunotherapy of transfer colitis". DDW 2002, San Francisco, USA. (Poster of distinction)

Nina N. Pawlowski, Katja Grollich, Sven Henschke, Anton J. Kroesen, Anja A. Kühl, Martin Zeitz, Jörg C. Hoffmann. "Relevance of CD28 for Colitis Development". Falk-Symposium 2003, Berlin.

Nina N. Pawlowski, Oliver Liesenfeld, Anja A. Kühl, Katja Grollich, Martin Zeitz, Jörg C. Hoffmann. „CD2-gerichtete Immuntherapie etablierter Transferkolitis und Untersuchungen zur Infektabwehr“. DGVS 2003, Nürnberg. (Präsidenten-Poster)

Nina N. Pawlowski, Anja A. Kühl, Katja Grollich, Christoph Loddenkemper, Martin Zeitz, Roland von Bülow, Jörg C. Hoffmann. „Abschwächung von Transferkolitis durch das anti-inflammatorische Peptid RDP58“. DGVS 2003, Nürnberg.

Anja A. Kuehl, Nina N. Pawlowski, Christoph Loddenkemper, Katja Grollich, Martin Zeitz, Joerg C. Hoffmann. "Effects of $\gamma\delta$ T cell depletion on colitis animal models increased inflammation and cytokine dysregulation". DDW 2003, Orlando, USA.

Anja A. Kühl, Nina N. Pawlowski, Katja Grollich, Christoph Loddenkemper, Martin Zeitz, Jörg C. Hoffmann. "Role of $\gamma\delta$ T Cells in DSS-induced Colitis". Falk-Symposium 2003, Berlin.

Anja A. Kühl, Nina N. Pawlowski, Katja Grollich, Christoph Loddenkemper, Martin Zeitz, Jörg C. Hoffmann. "Beeinflussen $\gamma\delta$ T-Zellen histologisch Entzündung und Überleben in CED-Tiermodellen?". DGVS 2003, Nürnberg.

Anja A. Kuehl, Nina N. Pawlowski, Christoph Loddenkemper, Katja Grollich, Thomas F. Tedder, Douglas A. Steeber, Martin Zeitz, Jörg C. Hoffmann. "Role of Neutrophils for the Initiation and Perpetuation of chemical induced Colitis". DDW 2004, New Orleans, USA.

Nina N. Pawlowski, Katja Grollich, Daniela, Anja Kühl, Martin Zeitz, Oliver Liesenfeld, Jörg C. Hoffmann: "Role of CD2 in *Toxoplasma gondii* infection". DGfI 2005, Kiel.

Kühl AA, Singer BB, Pawlowski NN, Grollich K, Loddenkemper C, Zeitz M, Lucka L, Hoffmann JC: „Behandlung mit anti-Ceacam1-Antikörper verschlimmert chemisch induzierte Kolitis in Ratten.“ DGVS 2005, Köln.

Vorträge:

„Anti-CD2-Therapie bei etablierter Transferkolitis“. 2002, DANCED in Mainz.

„Rolle von CD28 in der intestinalen T-Zellaktivierung“. 2003, DANCED in Mainz.

„Funktion von CD2 für die intestinale T-Zellaktivierung und deren Modulation bei Kolitis“. 2004, SFB-Jahrestreffen in Berlin.

Auszeichnungen:

Forschungspreis 2003 des CBF: N.N. Pawlowski, H. Kakirman, A.A. Kühl, O. Liesenfeld, K. Grollich, C. Loddenkemper, M. Zeitz, J.C. Hoffmann: "Treatment of adoptive transfer colitis with α -CD2 mAb".

Sonstiges:

Stipendium der Sonnenfeld-Stiftung (Januar bis Juli 2003)